CLAYMONT, Del. -- (BUSINESS WIRE) -- CD Diagnostics, Inc., an expert immunoassay developer and manufacturer, announced today the addition of new hires to its research and development team. These new hires join the CD Diagnostics’ team as the company settles in to its new headquarters facility in New Castle County, Delaware. The move consolidated administrative, research and development, and manufacturing operations under one roof. Since the signing of its first corporate partnership with Zimmer, a leading provider of orthopaedic devices and implants, CD Diagnostics has initiated additional programs to expand its pipeline of biomarker specific assays for use in orthopaedics, as well as the development of assays for other non-related applications. These key new hires will strengthen CD Diagnostics’ research and development team and position the company for future growth.
Martin Gould joins the company as an Immunoassay Development Fellow. Mr. Gould is a biomedical scientist with more than 40 years of experience in the diagnostic and chemical fields. He is an accomplished researcher with numerous publications in a variety of fields, including rapid immunoassay tests to detect food pathogens such as E-coli, salmonella, listeria, shigella, and campylobacter. He was awarded a patent in composition for stabilization of diagnostics reagents, three separate patents for immunoassay diagnostic kits, as well as a patent describing a growth media that resuscitates injured bacteria.
James W. Stave, Ph.D. joins the senior management team as Vice President of Corporate Development and Antibody Research Fellow. Prior to joining CD Diagnostics, Dr. Stave was a Senior Research Fellow at Strategic Diagnostics (NASDAQ: SDIX). He is an experienced, public biotechnology company business executive and expert immunoassay product development scientist. Jim has held positions as Chief Scientific Officer, Vice President of Research and Development, and Senior Research Fellow, and is responsible for the development of over 30 commercial test products. His fields of expertise include technology commercialization, product development, biotechnology and immunology.
“As we expand the number of programs that we are simultaneously working on and prepare for our relocation to Delaware, the addition of these individuals creates a very strong R&D team with more experience in point of care technology than could be found in most big companies,” said Rick Birkmeyer, President & CEO of CD Diagnostics, Inc. “We are very fortunate to have attracted such talent.”
“I am very excited to be working with such a talented and dedicated team of professionals where my technical and business development experience can accelerate ongoing programs and create new opportunities for growth,” says Dr. Stave.
Martin Gould says, “Being involved with this exciting new technology is a unique and exciting challenge. Seeing the tests that we are commercializing positively impacting patients’ lives is very rewarding.”
On Wednesday, May 7th, Delaware Economic Development Director Alan Levin and Larry Windley, Projects Director for Sen. Tom Carper, will join company officials and guests for a ribbon cutting at the facility. The ceremony will begin promptly at 4pm and will be held at 650 Naamans Road, located in the Brandywine Corporate Center in Claymont, Delaware. A tour of the facility will follow. Guests are encouraged to RSVP via email to email@example.com.
About CD Diagnostics, Inc.
CD Diagnostics, Inc. (www.cddiagnostics.com) combines expertise in immunoassay development with biomarker research, patented technology, and cGMP manufacturing to deliver a range of products that address challenging diagnostic issues. We are improving patient outcomes by providing more accurate and rapid diagnosis. CD Diagnostics is the parent company of Citrano Medical Laboratories, a CLIA-certified laboratory that has provided comprehensive clinical testing services to clients for 39 years. Our CLIA laboratory and sample acquisition programs with major hospitals and medical research institutions facilitate the rapid development and commercialization of laboratory developed tests.